Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Vutrisiran: Drug Interactions
Standard response letter on vutrisiran and drug interactions.
Standard response letter on vutrisiran and drug interactions.
Givosiran: Hemin Use
Standard response letter on givosiran and hemin use. This medical information response contains clinical data from the ENVISION study.
Standard response letter on givosiran and hemin use. This medical information response contains clinical data from the ENVISION study.
Patisiran: Patients with Heart Transplant
Standard response letter on patisiran and use in patients with heart transplant.
Standard response letter on patisiran and use in patients with heart transplant.
Patisiran & Vutrisiran: Chemical and Molecular Differences
Standard response letter on the differences between the chemistries of patisiran and vutrisiran.
Standard response letter on the differences between the chemistries of patisiran and vutrisiran.
Lumasiran: Use in Kidney Transplantation
Standard response letter on the use of lumasiran in patients who have had an isolated kidney transplant.
Standard response letter on the use of lumasiran in patients who have had an isolated kidney transplant.
Patisiran: Product Stability
Standard response letter on patisiran and product stability. The letter includes information on the chemical, physical and photostability of the active substance, patisiran, and the diluted patisiran solution.
Standard response letter on patisiran and product stability. The letter includes information on the chemical, physical and photostability of the active substance, patisiran, and the diluted patisiran solution.
Givosiran: Injection Site Reactions
Standard response letter on givosiran and injection site reactions during the phase 1, phase 1/2 open-label extension, and phase 3 ENVISION studies.
Standard response letter on givosiran and injection site reactions during the phase 1, phase 1/2 open-label extension, and phase 3 ENVISION studies.
